Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival

7208 Background: Response rates to combination platinum based chemotherapy vary from 20–40% leaving a large number with either stable or progressive disease. Short courses (3–4) have been shown to ...